{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.9","upperLimit":"4.9","value":"4.8"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"2.9","value":"2.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death. Investigator-assessed PFS was summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed cutaneous advanced or metastatic melanoma (Stage IIIC or Stage IV), with a BRAF (a human gene encoding for protein called B-Raf, which is involved in a signaling pathway and is important for cell growth) V600 E/K mutation-positive tumor sample as determined via the central BRAF mutation assay, received a Trametinib 2 milligram (mg) tablet once daily until disease progression, death, or withdrawal.","id":"OG000","title":"Trametinib"},{"description":"Participants with histologically confirmed cutaneous advanced or metastatic melanoma (Stage IIIC or Stage IV), with a BRAF V600 E/K mutation-positive tumor sample as determined via the central BRAF mutation assay, received an intravenous (IV) dose of Dacarbazine 1000 mg per square meter every 3 weeks or Paclitaxel 175 mg per square meter every 3 weeks at the discretion of the investigator, provided the participant had not received that type of chemotherapy before randomization, until disease progression, death, or withdrawal.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Primary Efficacy Population","reportingStatus":"POSTED","timeFrame":"Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)","title":"PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and With Prior Chemotherapy as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Months"}